Novartis India Ltd Technical Momentum Shifts Amid Mixed Indicator Signals

Current Market and Price Overview

As of 18 Aug 2026, Novartis India Ltd closed at ₹1,581.10, down marginally by 0.35% from the previous close of ₹1,586.70. The stock traded within a range of ₹1,577.60 to ₹1,625.00 during the day, remaining below its 52-week high of ₹1,777.50 but comfortably above the 52-week low of ₹750.00. This price action reflects a consolidation phase following a strong rally over the past year.

Technical Trend Shift: From Bullish to Mildly Bullish

The technical trend for Novartis India has shifted from a clear bullish stance to a mildly bullish one. This subtle change suggests that while upward momentum remains intact, the intensity of buying pressure has moderated. The daily moving averages continue to support a bullish outlook, indicating that the short-term trend remains positive. However, weekly and monthly indicators present a more mixed picture, signalling caution among traders.

MACD Analysis: Sustained Bullish Momentum

The Moving Average Convergence Divergence (MACD) indicator remains bullish on both weekly and monthly timeframes. This sustained bullishness implies that the stock’s momentum is still favouring upward price movement over the medium to long term. The MACD line continues to stay above the signal line, reinforcing the presence of buying interest despite recent price softness.

RSI Signals: Divergence Between Weekly and Monthly Views

The Relative Strength Index (RSI) presents a divergence in signals. On the weekly chart, the RSI is neutral, offering no clear buy or sell signal. Conversely, the monthly RSI is bearish, suggesting that the stock may be overextended or facing selling pressure on a longer-term basis. This divergence highlights the importance of considering multiple timeframes when analysing momentum and potential reversals.

Bollinger Bands and Moving Averages: Mildly Bullish to Bullish

Bollinger Bands indicate a mildly bullish stance on the weekly chart and a bullish stance on the monthly chart. This suggests that price volatility is contained within an upward trending range, with the stock price gravitating towards the upper band on the monthly scale. Daily moving averages remain bullish, supporting the notion that short-term price action is positive and that the stock is likely to find support near these averages.

KST and Dow Theory: Mixed Signals

The Know Sure Thing (KST) indicator shows a mildly bearish signal on the weekly timeframe but remains bullish on the monthly chart. This mixed reading implies short-term caution amid longer-term optimism. Meanwhile, Dow Theory analysis reveals no clear trend on either the weekly or monthly charts, indicating a lack of definitive directional confirmation from this classical technical framework.

Volume and On-Balance Volume (OBV) Trends

On-Balance Volume (OBV) does not indicate any significant trend on weekly or monthly charts, suggesting that volume flow is not strongly favouring either buyers or sellers at present. This neutral volume pattern aligns with the observed consolidation in price and the mildly bullish technical trend.

Comparative Returns: Outperforming Sensex Over Multiple Horizons

Novartis India Ltd has delivered impressive returns relative to the Sensex benchmark. Year-to-date, the stock has surged by 102.97%, vastly outperforming the Sensex’s decline of 8.79%. Over the past year, the stock gained 66.80% compared to the Sensex’s 3.56% loss. Even over longer horizons, Novartis India has outpaced the benchmark, with 3-year returns of 122.03% versus Sensex’s 19.30%, and 5-year returns of 90.56% against 39.32%. However, the 10-year return of 131.41% trails the Sensex’s 177.55%, reflecting a period of relative underperformance in the distant past.

Mojo Score and Grade Update

MarketsMOJO assigns Novartis India a Mojo Score of 64.0, reflecting a moderate level of confidence in the stock’s prospects. The Mojo Grade has been downgraded from Buy to Hold as of 17 Aug 2026, signalling a more cautious stance by the rating agency. This adjustment aligns with the observed technical trend shift and mixed indicator signals, suggesting that while the stock remains fundamentally sound, investors should monitor momentum closely before committing fresh capital.

Sector and Market Capitalisation Context

Operating within the Pharmaceuticals & Biotechnology sector, Novartis India is classified as a small-cap stock. This positioning implies higher volatility and growth potential compared to large-cap peers. The sector itself has been under pressure recently, with broader market indices showing subdued returns. Novartis India’s relative outperformance highlights its resilience and potential as a growth candidate within this space.

Technical Outlook and Investor Considerations

The current mildly bullish technical trend suggests that Novartis India is in a consolidation phase following a strong rally. The bullish MACD and moving averages provide a foundation for potential further gains, but the bearish monthly RSI and weekly KST caution against excessive optimism. Investors should watch for confirmation of trend continuation through a break above recent highs near ₹1,625 or a sustained move below key moving averages, which could signal a deeper correction.

Risk Factors and Market Dynamics

Given the stock’s small-cap status and sector volatility, price swings can be pronounced. The absence of clear volume trends and Dow Theory confirmation adds to the uncertainty. External factors such as regulatory developments, pharmaceutical sector dynamics, and broader market conditions will also influence price action. A balanced approach combining technical signals with fundamental analysis is advisable.

Conclusion: A Watchful Hold with Potential for Upside

Novartis India Ltd’s technical parameters reveal a stock at a crossroads. The shift to a mildly bullish trend and mixed indicator signals suggest that while the stock retains upside potential, caution is warranted. The downgrade to a Hold rating by MarketsMOJO reflects this balanced view. Investors should monitor key technical levels and sector developments closely, using the current consolidation phase to assess risk-reward dynamics before increasing exposure.

Only Rs. 9,999 - Get MojoOne + Stock of the Week for 1 Year Start at 33% Off →